The White House has withdrawn the nomination of Heidi Overton to lead the Food and Drug Administration, a White House official confirmed to Fox News, one day before a scheduled Senate committee vote. The move leaves the agency without a confirmed commissioner and puts the search for Marty Makary's successor back at the starting line.
President Donald Trump had praised Overton, a physician and White House advisor, as a "ROCKSTAR" when he picked her in August to succeed Makary, who resigned in May. Since Makary's departure, Kyle Diamantas has led the agency in an acting capacity. Overton's nomination had drawn scrutiny well before the vote, particularly over her positions on vaccines and abortion medication.
At her September confirmation hearing, Overton clashed with Senator Bernie Sanders, I-Vt., who pressed her to endorse universal healthcare as a human right. The sharpest exchanges, however, centered on childhood vaccines. Senate health committee Chairman Bill Cassidy, R-La., pointed to Overton's appearance alongside Trump in the Oval Office, where the president signed an executive order calling for changes to childhood vaccine recommendations, including splitting the combined measles, mumps and rubella vaccine. Cassidy said there was no scientific evidence for Trump's suggestion that the combined shot could be "quite lethal" and warned that such remarks could discourage vaccination.
Overton responded directly. "Yes, Senator, the MMR vaccine is safe and effective," she told Cassidy. Asked by Senator Maggie Hassan, D-N.H., whether Trump was wrong, Overton reiterated that the vaccine was safe and effective and described it as the best tool available during the measles outbreak. Senator Ed Markey, D-Mass., questioned why she had not corrected the president in the Oval Office. "So why should we expect you to stand up to the president as FDA commissioner?" Markey asked. When pressed on whether she would follow Trump if he asked her to disregard the agency's safety standards, Overton said she would give the president her best advice and follow the legal requirements for reviewing individual products.
Overton's background also drew attention. As a White House advisor she worked on several of the administration's Make America Healthy Again initiatives. Before returning to the White House, she served as vice chair and chief policy officer at the conservative America First Policy Institute, where she criticized expanded access to abortion pills in a 2023 policy brief. That record drew interest from anti-abortion groups, which had been pressing for changes at the FDA regardless of who led it.
Erik Baptist, senior vice president for legal strategy at SBA Pro-Life America, said the group wants the next FDA nominee to commit to ending mail-order access to abortion drugs and to changing how the agency studies their safety before the Senate holds a confirmation vote. "The administration must immediately end the Biden FDA's mail-order abortion-drug scheme and protect pregnant women from predators who coerce or poison women with these drugs," Baptist said in a statement. He added that the FDA "must fix its flawed safety study by obtaining robust data, increasing real-time transparency, and inviting external experts." "Confirmation is not a coronation," he said. "It is a time to vet nominees and seek commitments before they take office."
The withdrawal means the Senate Health, Education, Labor and Pensions Committee will not take up Overton's nomination as planned, and the White House has not yet named a replacement in the reporting available. With Diamantas continuing in an acting role, the FDA's direction on vaccine guidance and abortion drug policy remains a live question for lawmakers and advocacy groups on both sides of those debates.